Esokem-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and improving esophageal sphincter tone, thereby reducing symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance through once-daily dosing. Esokem-D is indicated in patients requiring both acid suppression and prokinetic effects, particularly in cases where delayed gastric emptying exacerbates reflux symptoms. Caution is advised in patients with known hypersensitivity to either component, significant hepatic impairment, or cardiac arrhythmias. Common adverse effects may include headache, dry mouth, and abdominal discomfort. Esokem-D should be administered under medical supervision, with dosage adjustments based on clinical response and tolerability. This combination therapy offers a comprehensive approach to managing complex upper GI disorders by addressing both acid secretion and motility dysfunction.